Charles Schwab Investment Management Inc. Buys 33,105 Shares of Sanofi (NASDAQ:SNY)

Charles Schwab Investment Management Inc. lifted its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 31.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 139,505 shares of the company's stock after purchasing an additional 33,105 shares during the quarter. Charles Schwab Investment Management Inc.'s holdings in Sanofi were worth $8,040,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. GFS Advisors LLC boosted its holdings in Sanofi by 1,017.9% in the third quarter. GFS Advisors LLC now owns 12,800 shares of the company's stock worth $738,000 after acquiring an additional 11,655 shares in the last quarter. Legacy Capital Wealth Partners LLC lifted its stake in shares of Sanofi by 114.2% in the third quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company's stock worth $1,399,000 after buying an additional 12,942 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its stake in shares of Sanofi by 15.2% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 116,917 shares of the company's stock worth $5,673,000 after buying an additional 15,439 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Sanofi in the 3rd quarter valued at approximately $8,728,000. Finally, Strategic Financial Concepts LLC bought a new position in Sanofi in the 2nd quarter valued at approximately $1,256,000. 10.04% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

SNY stock traded down $0.09 during trading on Wednesday, reaching $47.99. The stock had a trading volume of 1,454,386 shares, compared to its average volume of 2,056,101. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The stock's 50 day moving average is $51.53 and its two-hundred day moving average is $52.12. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a market cap of $121.79 billion, a PE ratio of 24.53, a PEG ratio of 1.23 and a beta of 0.58.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to analysts' expectations of $16.59 billion. During the same quarter in the prior year, the business earned $2.55 EPS. The business's quarterly revenue was up 12.3% on a year-over-year basis. As a group, equities analysts anticipate that Sanofi will post 4.27 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on SNY shares. StockNews.com downgraded Sanofi from a "buy" rating to a "hold" rating in a report on Friday, December 6th. Citigroup upgraded shares of Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Sanofi currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.